<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=905310923417895&amp;ev=PageView&amp;noscript=1">

Formedix CEO Mark Wheeldon in PharmaVOICE 100!

Aug 5, 2014 12:00:00 AM




Find me on

He’s all about efficiency…



The prestigious list recognizes the 100 most inspiring and innovative figures in the Life Sciences industry. Wheeldon’s inclusion puts him among the elite of the Life Sciences world, alongside key figures from giants such as Pfizer, Johnson & Johnson and Microsoft.

The magazine describes Mark as a “major contributor and recognized innovator in developing an efficient clinical trial process,” and an “energetic, inspiring leader… [who] continues to disrupt industry paradigms in data management.”

“His efforts have provided a system available to all that historically was only created on a proprietary level by big pharma companies at a big expense. His vision has enabled study sponsors to control and manage study metadata standards, and capitalize on this to seamlessly electronically capture data based on their standards. His innovation has significantly changed the landscape of what’s possible: making the link between standards, tools, practicality, and independence,” it continues.

“Mark is fully deserving of a place on the PharmaVOICE 100,” said Nicola Rogerson, Marketing Manager at Formedix. “His constant energy, passion and conviction, the innovation that he brings, and his all-round hard work make him a true inspiration to us.”

“I’m truly honored to be named on the PharmaVOICE 100,” said Wheeldon.“It’s a privilege to be recognized among the industry’s key figures, alongside some of the most respected decision makers from top companies. I founded Formedix almost 15 years ago: taking a start-up company beyond survival with very limited resources and selling innovative and new products to a conservative industry has been challenging.

“I’d like to thank everyone who nominated me, and of course the amazing team at Formedix, who work so hard to develop and deliver our market-leading software.”

You can read Mark’s full PharmaVOICE 100 entry here.


Similar blogs you might like...